Monte Rosa Therapeutics (GLUE) just posted its FY 2025 third quarter numbers, with revenue of US$12.8 million and a basic EPS loss of US$0.33 off a net income loss of US$27.1 million, setting a clear snapshot of where the business stands today. Over recent periods, the company has seen revenue move from US$60.6 million in Q4 2024 to US$84.9 million in Q1 2025, then to US$23.2 million in Q2 2025 and US$12.8 million in Q3 2025. Over the same timeframe, basic EPS shifted from a profit of US$0.16 in Q4 2024 to US$0.57 in Q1 2025, before losses of US$0.15 and US$0.33 in Q2 and Q3 2025 respectively, leaving investors focused squarely on how sustainably margins can hold up from here.

See our full analysis for Monte Rosa Therapeutics.

With the headline numbers on the table, the next step is to see how this earnings profile lines up against the key Monte Rosa Therapeutics narratives that investors have been following and where those stories might be reinforced or tested by the latest data.

TTM revenue hits US$181.5 million

• Over the last twelve months to Q3 2025, total revenue sits at US$181.5 million, compared with quarterly figures that range from US$4.7 million in Q2 2024 to US$84.9 million in Q1 2025. This shows how much the trailing view can look smoother than any single quarter.
• What stands out for the generally bullish view is that this TTM revenue base lines up with forecasts of about 44.3% annual revenue growth, yet the latest quarter shows US$12.8 million, which is well below the Q1 2025 high of US$84.9 million.
  • Supporters pointing to strong revenue growth forecasts can reference the TTM figure of US$181.5 million, but also need to factor in how quarterly revenue can swing between single digit millions and above US$80 million.
  • This pattern means anyone leaning on a bullish growth story has to reconcile the 44.3% revenue growth forecast with a recent sequence of US$23.2 million in Q2 2025 and US$12.8 million in Q3 2025.

Sentiment around that 44.3% revenue growth forecast versus the uneven quarterly revenue line is exactly what broader market narratives try to unpack for Monte Rosa Therapeutics, and seeing how others connect those dots can help you pressure test your own view before acting on it.Curious how numbers become stories that shape markets? Explore Community Narratives

Profit flips positive on a TTM basis

• On a trailing twelve month basis through Q3 2025, net income is US$20.9 million and basic EPS is US$0.25, compared with individual quarters that span from a loss of US$27.1 million in Q3 2025 to a profit of US$46.9 million in Q1 2025.
• For investors taking a bullish stance, the move from a TTM loss of US$119.4 million in Q3 2024 and US$72.7 million in Q4 2024 to a TTM profit of US$20.9 million by Q3 2025 strongly backs the idea that the company has recently turned profitable, while the forecast 3.3% annual EPS decline over the next three years pulls in the opposite direction.
  • The five year earnings growth rate of 6.1% a year and a TTM EPS of US$0.25 support the bullish narrative that the business is not just shrinking its losses, it has actually posted positive earnings across the last twelve months.
  • At the same time, analysts’ expectation of earnings declining about 3.3% a year over the next three years introduces a clear tension that bulls need to think through when they look at the latest quarterly loss of US$27.1 million in Q3 2025.

Rich P/E versus peers despite DCF gap

• With a current share price of US$16.03 and a reported P/E of 60.6x compared with a peer average of 38.1x and a US biotech industry average of 20.6x, the stock is priced at a higher multiple. At the same time, analysts’ DCF fair value of about US$49.25 sits well above the market level and the single allowed analyst target of US$33.00 also exceeds the current price.
• Skeptical, more bearish takes often focus on that 60.6x P/E and the forecast 3.3% annual earnings decline, and the data gives them and the opposing camp plenty to debate.
  • Critics highlight that paying a 60.6x P/E when earnings are modeled to shrink by around 3.3% a year contrasts sharply with the broader biotech group where the P/E is 20.6x. They therefore question how much of the 44.3% revenue growth forecast is already embedded into the valuation.
  • Supporters point to the gap between the US$16.03 share price and both the US$49.25 DCF fair value and the US$33.00 analyst target. They argue that trading around 67.5% below that DCF number is hard to square with the elevated multiple, which is why valuation debates around this name can be so intense.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Monte Rosa Therapeutics's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

With sentiment so split between the risks and rewards outlined here, it makes sense to move quickly, cross check the latest figures, and stress test whether the bullish or bearish angle feels more convincing for you personally by reviewing the 4 key rewards and 4 important warning signs

See What Else Is Out There

The combination of a quarterly loss of US$27.1 million, uneven revenue, and a 60.6x P/E with forecast EPS decline highlights meaningful earnings and valuation pressures.

If that mix of high expectations and earnings strain feels uncomfortable, you can quickly compare it with companies that score well in our 77 resilient stocks with low risk scores and see if a steadier profile suits you better.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.